| P50 | author | Eleanor Bolton | Q54448590 |
| P2093 | author name string | John Andrew Bradley | |
| P2860 | cites work | Mesenchymal stem cells avoid allogeneic rejection | Q21245658 |
| | Prevention of allogeneic fetal rejection by tryptophan catabolism | Q24336018 |
| | Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells | Q24634829 |
| | Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential | Q24680634 |
| | OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset | Q24682576 |
| | CMV: Prevention, Diagnosis and Therapy | Q26824869 |
| | The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies | Q26851666 |
| | The immunogenicity of cells derived from induced pluripotent stem cells | Q27003999 |
| | Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells | Q58234949 |
| | Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts | Q59068399 |
| | Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells | Q59102107 |
| | Epstein-Barr virus infection and posttransplant lymphoproliferative disorder | Q27024229 |
| | Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 |
| | Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 |
| | Multilineage potential of adult human mesenchymal stem cells | Q27860737 |
| | Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo? | Q28084829 |
| | Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells | Q28184794 |
| | Mother's little helpers: mechanisms of maternal-fetal tolerance | Q28297770 |
| | Fat tissue: an underappreciated source of stem cells for biotechnology | Q28298098 |
| | 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation | Q28370605 |
| | Rethinking differentiation: stem cells, regeneration, and plasticity | Q28656516 |
| | Epigenetic memory in induced pluripotent stem cells | Q29547892 |
| | ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering | Q29615505 |
| | A more efficient method to generate integration-free human iPS cells | Q29615748 |
| | Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 |
| | Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 |
| | Human mesenchymal stem cells modulate B-cell functions | Q29620705 |
| | Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice | Q29622850 |
| | Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice | Q30413179 |
| | Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. | Q30489278 |
| | In situ-targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy | Q33424530 |
| | Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types | Q33454974 |
| | Transcriptional signature and memory retention of human-induced pluripotent stem cells | Q33504601 |
| | Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells | Q33564357 |
| | HLA-mismatched renal transplantation without maintenance immunosuppression | Q33640791 |
| | Mesenchymal stem cell therapy: Two steps forward, one step back | Q33898653 |
| | Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance | Q34027002 |
| | Characterization of the expression of MHC proteins in human embryonic stem cells | Q34076010 |
| | Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation | Q34124667 |
| | Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. | Q34184100 |
| | Immunological considerations for embryonic and induced pluripotent stem cell banking | Q34197332 |
| | Actively acquired tolerance of foreign cells | Q34233179 |
| | Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. | Q34290459 |
| | Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells | Q34321823 |
| | The requirement for NKG2D in NK cell–mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient | Q34450450 |
| | Invasive fungal infections in solid organ transplant recipients | Q34461693 |
| | Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials | Q34469147 |
| | Emerging role of innate immunity in organ transplantation part II: potential of damage-associated molecular patterns to generate immunostimulatory dendritic cells. | Q37954811 |
| | Immune regulatory function of B cells. | Q37973774 |
| | Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations | Q38007560 |
| | The role of complement in the early immune response to transplantation. | Q38013049 |
| | Review article: use of induction therapy in liver transplantation | Q38032009 |
| | A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor | Q38044248 |
| | Belatacept in kidney transplantation | Q38050305 |
| | The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells | Q38078099 |
| | The impact of calcineurin inhibitors on graft survival | Q38112540 |
| | Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives | Q38113726 |
| | Is it time to give up with calcineurin inhibitors in kidney transplantation? | Q38156847 |
| | Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy | Q38214635 |
| | The early days of NK cells: an example of how a phenomenon led to detection of a novel immune receptor system - lessons from a rat model | Q38225120 |
| | Transplantation between monozygotic twins: how identical are they? | Q38237790 |
| | Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. | Q39193477 |
| | The role of human leukocyte antigen matching in the development of multiethnic "haplobank" of induced pluripotent stem cell lines | Q39449356 |
| | Regulation of HLA class II expression prevents allogeneic T-cell responses | Q39620423 |
| | Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells | Q39741470 |
| | Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes | Q39920513 |
| | Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack | Q40083810 |
| | Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. | Q40173892 |
| | Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells | Q40229749 |
| | Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. | Q40395995 |
| | They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. | Q40409278 |
| | Tolerance and chimerism after renal and hematopoietic-cell transplantation | Q40428891 |
| | Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? | Q40643054 |
| | Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway | Q40716666 |
| | Optimising the use of mTOR inhibitors in renal transplantation | Q41928074 |
| | Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate | Q42072961 |
| | Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells | Q42172253 |
| | Gene targeting in human-induced pluripotent stem cells with adenoviral vectors | Q42235958 |
| | Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9 | Q42276892 |
| | An estimation of the frequency of precursor cells which generate cytotoxic lymphocytes | Q42940743 |
| | In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation | Q43161029 |
| | Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells | Q44485559 |
| | Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression | Q44592649 |
| | Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation | Q44807533 |
| | Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney | Q45178758 |
| | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study | Q45354237 |
| | Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells | Q45753529 |
| | Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival | Q45864742 |
| | Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness | Q45879145 |
| | Lentivirus-mediated gene transfer of viral interleukin-10 delays but does not prevent cardiac allograft rejection. | Q45883107 |
| | To be immunogenic, or not to be: that's the iPSC question | Q46184419 |
| | Viral IL-10 gene transfer prolongs rat islet allograft survival | Q46345370 |
| | Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. | Q46488249 |
| | The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function | Q46576236 |
| | Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. | Q46670167 |
| | Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival | Q46953071 |
| | Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies | Q47563168 |
| | HLA-haplotype banking and iPS cells | Q47586309 |
| | Amplification of RNAi--targeting HLA mRNAs | Q47618413 |
| | Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. | Q47655352 |
| | Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells | Q47701428 |
| | Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells | Q47864474 |
| | Kinetics of intragraft cytokine expression, cellular infiltration, and cell death in rejection of renal allografts compared with acceptance of liver allografts in a rat model: early activation and apoptosis is associated with liver graft acceptance | Q47980487 |
| | Mesenchymal stromal cells: cautious optimism for their potential role in the treatment of acute lung injury. | Q50586044 |
| | Vitamin C in human and guinea pig aqueous, lens and plasma in relation to intake. | Q50936323 |
| | Mechanisms of rejection: current perspectives. | Q50979807 |
| | Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. | Q52008649 |
| | Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. | Q53478474 |
| | Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. | Q53753309 |
| | Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte- and cardiomyocyte-like cells. | Q54505891 |
| | Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. | Q54671130 |
| | Sirolimus and secondary skin-cancer prevention in kidney transplantation. | Q55056496 |
| | Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment | Q56906119 |
| | Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells | Q57702466 |
| | Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. | Q34554699 |
| | Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation | Q34558827 |
| | Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease | Q34693075 |
| | Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells | Q34700964 |
| | Improved survival of mesenchymal stromal cell after hypoxia preconditioning: Role of oxidative stress | Q34753654 |
| | Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade | Q34976218 |
| | Stem cell medicine encounters the immune system | Q34988364 |
| | Toward the development of a global induced pluripotent stem cell library | Q35008270 |
| | Skin cancers after organ transplantation | Q35113533 |
| | Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice | Q35187089 |
| | Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras | Q35846129 |
| | Update on islet transplantation | Q36065843 |
| | HLA-G and immune tolerance in pregnancy | Q36109416 |
| | Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells | Q36306295 |
| | Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors | Q36335542 |
| | Histocompatibility antigen-activated cytotoxic T lymphocytes. I. Estimates of the absolute frequency of killer cells generated in vitro | Q36335552 |
| | A case for regulatory B cells | Q36360842 |
| | Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. | Q36385029 |
| | Dendritic cells in a mature age. | Q36475977 |
| | Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance | Q36693370 |
| | Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation | Q36722979 |
| | Clinical transplantation tolerance: many rivers to cross | Q36795236 |
| | Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts | Q36861712 |
| | Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells | Q37077290 |
| | Toward eliminating HLA class I expression to generate universal cells from allogeneic donors | Q37113074 |
| | Development of gene therapy for blood disorders: an update | Q37132611 |
| | Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice | Q37163714 |
| | Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model | Q37174844 |
| | Pathways of major histocompatibility complex allorecognition. | Q37236992 |
| | Transplantation of human islets without immunosuppression | Q37340689 |
| | Recent advances in lentiviral vector development and applications | Q37678176 |
| | B-cell immunotherapeutics: emerging roles in solid organ transplantation | Q37888431 |
| | Emerging role of innate immunity in organ transplantation part III: the quest for transplant tolerance via prevention of oxidative allograft injury and its consequences | Q37945969 |
| | Emerging role of innate immunity in organ transplantation: part I: evolution of innate immunity and oxidative allograft injury | Q37945971 |
| P433 | issue | 3 | |
| P921 | main subject | immunology | Q101929 |
| | regenerative medicine | Q1061415 |
| P304 | page(s) | 287-304 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Regenerative Medicine | Q19921466 |
| P1476 | title | Avoiding immunological rejection in regenerative medicine | |
| P478 | volume | 10 | |